Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) (SYMPATICO)

NCT03112174 PHASE3 COMPLETED Results posted

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.

Details

Lead sponsor	Pharmacyclics LLC.
Phase	PHASE3
Status	COMPLETED
Enrolment	366
Start date	Mon Jun 19 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jun 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Mantle-Cell Lymphoma

Interventions

• Ibrutinib
• Venetoclax
• Placebo Oral tablet to match Venetoclax

Countries

France, Italy, Netherlands, Greece, Ukraine, Belgium, United Kingdom, Germany, Hungary, Poland, South Korea, Canada, Australia, United States, Turkey (Türkiye), Spain, Czechia